US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

YD Bio Ltd

4.69

-0.0958-2.00%

Post-market: 4.50-0.1900-4.05%19:30 EDT

Volume:36.01K

Turnover:171.76K

Market Cap:330.75M

PE:-40.09

High:5.00

Open:4.56

Low:4.40

Close:4.79

52wk High:25.00

52wk Low:1.70

Shares:70.52M

Float Shares:16.11M

Volume Ratio:0.43

T/O Rate:0.22%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1170

EPS(LYR):-1.2901

ROE:-42.69%

ROA:-25.43%

PB:50.19

PE(LYR):-3.64

Loading ...

Overview Company News Filings

Yd Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

THOMSON REUTERS

YD Bio Highlights Peer-Reviewed Computational Study Nominating Keratoconus Regenerative Therapy Targets

YD Bio Launches Cancer Testing Pilot with Numia Health in Canada

YD Bio Wins Rhode Island, Pennsylvania Lab Licenses, Expanding U.S. Footprint to 46 States

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:48 PM

Yd Bio Limited Reports Full Year 2025 Financial Results

THOMSON REUTERS

YD Bio FY25 net loss widens to $8.3 million; revenue rises 17% to $596,817

YD Bio Ltd trading halted, volatility trading pause

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:56 PM

YD Bio files Form 3 as director Kochi Chang reports no beneficial ownership

YD Bio files Form 3; director Jerry Yin-Chia Lee reports no securities owned

YD Bio files initial beneficial ownership statement; Chief Medical Officer and director Zhang Bo-Xiang reports 31,141 ordinary shares

YD Bio files initial beneficial ownership statement; CFO Edmund Hen reports no securities beneficially owned

YD Bio Ltd trading halted, volatility trading pause

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:43 AM

YD Bio Limited files Form 3 as CEO Ethan Shen reports 54.34 million ordinary shares owned

YD Bio details roadmap for integrated oncology ecosystem

YD Bio outlines plan to integrate cancer detection with dendritic cell immunotherapy by 2027

BRIEF-Yd Bio Limited Announces Strategic Partnership With Yc Biotech Co

BUZZ-YD Bio rises as it signs U.S. regulatory partnership

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/YDES/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"YDES","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"YDES\",,,,,undefined,":{"symbol":"YDES","market":"US","secType":"STK","nameCN":"YD Bio Ltd","latestPrice":4.69,"timestamp":1787342400000,"preClose":4.7858,"halted":0,"volume":36005,"hourTrading":{"tag":"盘后","latestPrice":4.5,"preClose":4.69,"latestTime":"19:30 EDT","volume":694,"amount":3146.87,"timestamp":1787355007479,"change":-0.19,"changeRate":-0.040512,"amplitude":0.040512},"delay":0,"changeRate":-0.020017551924443072,"floatShares":16106600,"shares":70521359,"eps":-0.117,"marketStatus":"Market Closed","change":-0.0958,"latestTime":"08-21 16:00:00 EDT","open":4.56,"high":5,"low":4.4,"amount":171760.376295,"amplitude":0.125371,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.117,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1756440000000,"exchange":"NASDAQ","adjPreClose":4.7858,"preHourTrading":{"tag":"盘前","latestPrice":4.41,"preClose":4.7858,"latestTime":"09:06 EDT","volume":560,"amount":2528.0365599999996,"timestamp":1787317569090,"change":-0.3758,"changeRate":-0.078524,"amplitude":0.108655},"postHourTrading":{"tag":"盘后","latestPrice":4.5,"preClose":4.69,"latestTime":"19:30 EDT","volume":694,"amount":3146.87,"timestamp":1787355007479,"change":-0.19,"changeRate":-0.040512,"amplitude":0.040512},"volumeRatio":0.4337491926999008},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"YDES\",,,,,undefined,":{"symbol":"YDES","floatShares":16106600,"roa":"-25.43%","roe":"-42.69%","lyrEps":-1.290101,"volumeRatio":0.4337491926999008,"shares":70521359,"dividePrice":0,"high":5,"amplitude":0.125371,"preClose":4.7858,"low":4.4,"week52Low":1.7,"pbRate":"50.19","psRate":"648.06","week52High":25,"institutionHeld":0,"latestPrice":4.69,"eps":-0.117,"divideRate":0,"volume":36005,"delay":0,"ttmEps":-0.117,"open":4.56,"prevYearClose":12.19,"prevWeekClose":2.98,"prevMonthClose":2.17,"prevQuarterClose":2.25,"fiveDayClose":2.98,"twentyDayClose":2.24,"sixtyDayClose":3.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/YDES\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-04-30","symbol":"YDES","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1777521600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-19","symbol":"YDES","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755576000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"YDES\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"YDES\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/YDES\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"YDES","date":"2026-08-21","current":-40.08547,"percent":0.735043,"low":-1151.273969,"twenty":-621.817467,"median":-406.004661,"eighty":-158.468303,"high":-94.652554,"avg":-436.399748,"sd":260.709718,"marketCap":336536613},"quantilePoints":[{"date":"2025-09-19","current":-961.968859,"twenty":-999.829881,"median":-916.635267,"eighty":-851.374822,"marketCap":1357875801},{"date":"2025-09-26","current":-709.645075,"twenty":-998.136098,"median":-925.353266,"eighty":-851.374822,"marketCap":1001705892},{"date":"2025-10-03","current":-960.225259,"twenty":-973.028263,"median":-916.635267,"eighty":-851.374822,"marketCap":1355414607},{"date":"2025-10-10","current":-932.078579,"twenty":-963.563007,"median":-911.653554,"eighty":-851.474456,"marketCap":1315683907},{"date":"2025-10-17","current":-939.800234,"twenty":-960.573979,"median":-919.624296,"eighty":-852.27153,"marketCap":1326583479},{"date":"2025-10-24","current":-877.279731,"twenty":-963.563007,"median":-920.745181,"eighty":-864.327276,"marketCap":1238332100},{"date":"2025-10-31","current":-553.468359,"twenty":-960.573979,"median":-906.67184,"eighty":-851.474456,"marketCap":781253244},{"date":"2025-11-07","current":-468.779231,"twenty":-944.084508,"median":-894.715728,"eighty":-771.61759,"marketCap":661709543},{"date":"2025-11-14","current":-504.149397,"twenty":-939.850051,"median":-872.298018,"eighty":-562.236175,"marketCap":711636618},{"date":"2025-11-21","current":-416.471241,"twenty":-935.217058,"median":-854.36385,"eighty":-532.644798,"marketCap":587873728},{"date":"2025-11-28","current":-574.391556,"twenty":-932.875653,"median":-852.122079,"eighty":-497.174998,"marketCap":810787570},{"date":"2025-12-05","current":-636.164802,"twenty":-928.790648,"median":-849.382136,"eighty":-516.703315,"marketCap":897984152},{"date":"2025-12-12","current":-626.201375,"twenty":-924.506374,"median":-777.645464,"eighty":-530.751747,"marketCap":883920187},{"date":"2025-12-19","current":-564.677215,"twenty":-922.364238,"median":-692.707249,"eighty":-539.021391,"marketCap":797075205},{"date":"2025-12-26","current":-621.717833,"twenty":-920.969359,"median":-645.630058,"eighty":-546.593595,"marketCap":877591403},{"date":"2026-01-02","current":-607.270864,"twenty":-919.02649,"median":-636.164802,"eighty":-555.660313,"marketCap":857198654},{"date":"2026-01-09","current":-614.245263,"twenty":-914.642582,"median":-629.688575,"eighty":-564.477946,"marketCap":867043429},{"date":"2026-01-16","current":-568.911671,"twenty":-905.326777,"median":-626.699546,"eighty":-565.524106,"marketCap":803052390},{"date":"2026-01-23","current":-612.750749,"twenty":-899.946527,"median":-622.714176,"eighty":-564.677215,"marketCap":864933835},{"date":"2026-01-30","current":-549.482989,"twenty":-896.708414,"median":-621.717833,"eighty":-564.677215,"marketCap":775627658},{"date":"2026-02-06","current":-536.032363,"twenty":-892.723043,"median":-616.73612,"eighty":-563.929958,"marketCap":756641306},{"date":"2026-02-13","current":-488.706085,"twenty":-877.279731,"median":-614.494349,"eighty":-554.464703,"marketCap":689837473},{"date":"2026-02-20","current":-438.39078,"twenty":-873.294361,"median":-611.928766,"eighty":-547.988475,"marketCap":618814451},{"date":"2026-02-27","current":-449.84872,"twenty":-868.312647,"median":-609.761721,"eighty":-532.644798,"marketCap":634988010},{"date":"2026-03-06","current":-417.392858,"twenty":-858.548489,"median":-606.523607,"eighty":-488.307548,"marketCap":589174645},{"date":"2026-03-13","current":-374.126677,"twenty":-853.168238,"median":-599.051037,"eighty":-460.210684,"marketCap":528101878},{"date":"2026-03-20","current":-270.008867,"twenty":-852.371164,"median":-597.058352,"eighty":-440.283831,"marketCap":381133446},{"date":"2026-03-27","current":-385.086446,"twenty":-851.972627,"median":-591.329381,"eighty":-432.31309,"marketCap":543572239},{"date":"2026-04-02","current":-363.166907,"twenty":-850.677382,"median":-588.838525,"eighty":-423.505421,"marketCap":512631516},{"date":"2026-04-10","current":-287.943035,"twenty":-849.581405,"median":-577.62967,"eighty":-418.782756,"marketCap":406448582},{"date":"2026-04-17","current":-264.030811,"twenty":-817.997342,"median":-572.897042,"eighty":-404.415494,"marketCap":372695067},{"date":"2026-04-24","current":-261.290868,"twenty":-791.09609,"median":-569.160757,"eighty":-391.761942,"marketCap":368827476},{"date":"2026-05-01","current":-254.067384,"twenty":-775.752412,"median":-564.428129,"eighty":-384.588275,"marketCap":358631102},{"date":"2026-05-08","current":-263.607365,"twenty":-733.059128,"median":-562.933615,"eighty":-378.610219,"marketCap":372097348},{"date":"2026-05-15","current":-252.074698,"twenty":-699.482379,"median":-554.464703,"eighty":-359.839123,"marketCap":355818309},{"date":"2026-05-22","current":-225.173446,"twenty":-672.830213,"median":-549.98116,"eighty":-320.324172,"marketCap":317845604},{"date":"2026-05-29","current":-174.858141,"twenty":-653.999336,"median":-541.263162,"eighty":-287.345229,"marketCap":246822582},{"date":"2026-06-05","current":-156.674886,"twenty":-645.630058,"median":-534.537849,"eighty":-272.001552,"marketCap":221155846},{"date":"2026-06-12","current":-161.905686,"twenty":-641.843956,"median":-497.174998,"eighty":-270.30777,"marketCap":228539428},{"date":"2026-06-18","current":-125.539178,"twenty":-635.268094,"median":-487.709742,"eighty":-264.528982,"marketCap":177205956},{"date":"2026-06-26","current":-120.557464,"twenty":-631.282723,"median":-463.299347,"eighty":-261.754167,"marketCap":170173974},{"date":"2026-07-02","current":-115.077579,"twenty":-629.688575,"median":-449.84872,"eighty":-258.745212,"marketCap":162438793},{"date":"2026-07-10","current":-106.608667,"twenty":-629.688575,"median":-440.383465,"eighty":-257.056411,"marketCap":150484423},{"date":"2026-07-17","current":-122.55015,"twenty":-628.692232,"median":-438.39078,"eighty":-252.074698,"marketCap":172986767},{"date":"2026-07-24","current":-101.626953,"twenty":-626.699546,"median":-432.163639,"eighty":-236.631387,"marketCap":143452440},{"date":"2026-07-31","current":-109.597694,"twenty":-626.301009,"median":-425.986313,"eighty":-211.02538,"marketCap":154703612},{"date":"2026-08-07","current":-117.772686,"twenty":-623.411616,"median":-420.954783,"eighty":-167.688458,"marketCap":166243095},{"date":"2026-08-14","current":-125.041006,"twenty":-622.315638,"median":-418.551107,"eighty":-158.468303,"marketCap":176502758},{"date":"2026-08-21","current":-238.41484,"twenty":-621.817467,"median":-406.004661,"eighty":-158.468303,"marketCap":336536613}],"updateTime":1787470274745},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"YDES\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658997056","title":"Yd Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997056","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997056?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449605,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nTUA3WPFCM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","YDES"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656455599","title":"YD Bio Highlights Peer-Reviewed Computational Study Nominating Keratoconus Regenerative Therapy Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2656455599","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656455599?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:07","pubTimestamp":1785845249,"startTime":"0","endTime":"0","summary":"YD Bio highlights peer-reviewed computational study nominating keratoconus regenerative therapy targetsYD Bio highlighted a new peer-reviewed computational study on keratoconus in Bioengineering; no c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL5mXG3r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU2210150020.SGD","SG9999014039.USD","SG9999014013.SGD","YDES","IE00BKPKM429.USD","BK4588","IE00B64PRP62.GBP","SG9999014005.SGD","BK4112","NDAQ","BCDF","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014021.USD","LU0314104364.USD","BK4139","IE00B3QW5Z07.USD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001263","title":"YD Bio Launches Cancer Testing Pilot with Numia Health in Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001263","media":"Reuters","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654001263?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:01","pubTimestamp":1785240074,"startTime":"0","endTime":"0","summary":"YD Bio launches cancer testing pilot with Numia Health in CanadaYD Bio launched a six-month pilot with Numia Health to build a cross-border workflow for physician-ordered blood-based cancer testing in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL1r5N7l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BN0W2W23.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","IE00BN0W2T93.GBP","LU2095319765.USD","BK4112","NDAQ","YDES","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","BK4139","LU2210150020.SGD","SG9999014021.USD","BCDF","LU0314104364.USD","SG9999014039.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648502274","title":"YD Bio Wins Rhode Island, Pennsylvania Lab Licenses, Expanding U.S. Footprint to 46 States","url":"https://stock-news.laohu8.com/highlight/detail?id=2648502274","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648502274?lang=en_us&edition=fundamental","pubTime":"2026-07-02 20:01","pubTimestamp":1782993679,"startTime":"0","endTime":"0","summary":"YD Bio wins Rhode Island, Pennsylvania lab licenses, expanding U.S. footprint to 46 statesYD Bio affiliate EG BioMed US secured out-of-state clinical laboratory licenses in Rhode Island, Pennsylvania ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDLbGf6BG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BKPKM429.USD","SG9999014039.USD","IE00BGHQF748.EUR","LU2210149790.SGD","NDAQ","IE00BN0W2V16.EUR","LU2210150020.SGD","LU2095319765.USD","BK4585","IE00B3QW5Z07.USD","BK4139","IE00BN0W2T93.GBP","SG9999014013.SGD","LU0314104364.USD","IE00BN0W2W23.USD","BK4588","IE00B64PRP62.GBP","YDES","SG9999014021.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640860481","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 02:48 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2640860481","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640860481?lang=en_us&edition=fundamental","pubTime":"2026-06-04 02:48","pubTimestamp":1780512481,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 02:48 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nAQN2M1ZOW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","YDES"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632662735","title":"Yd Bio Limited Reports Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2632662735","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632662735?lang=en_us&edition=fundamental","pubTime":"2026-05-01 06:00","pubTimestamp":1777586400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUA3FLTRZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","YDES"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632662168","title":"YD Bio FY25 net loss widens to $8.3 million; revenue rises 17% to $596,817","url":"https://stock-news.laohu8.com/highlight/detail?id=2632662168","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632662168?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:46","pubTimestamp":1777585560,"startTime":"0","endTime":"0","summary":"YD Bio posted a net loss of USD 8.31 million for fiscal 2025, widening from a net loss of USD 1.41 million a year earlier.Operating loss widened to USD 5.27 million from USD 1.46 million.Cash and cash equivalents climbed to USD 6 million from USD 3.1 million, following a PIPE financing that secured USD 13.2 million in gross proceeds.For 2026, YD Bio forecast USD 2.4 million to USD 2.7 million of operating cash needs and USD 9 million to USD 10 million of capital expenditures, primarily tied to real estate and production-facility investment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. YD Bio Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL1LNZbv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YDES","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625965031","title":"YD Bio Ltd trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2625965031","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625965031?lang=en_us&edition=fundamental","pubTime":"2026-04-08 04:01","pubTimestamp":1775592082,"startTime":"0","endTime":"0","summary":"15:56 EDT YD Bio (YDES)Ltd trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/yd-bio-ltd-trading-halted-volatility-trading-pause-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/yd-bio-ltd-trading-halted-volatility-trading-pause-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","YDES"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625965556","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 03:56 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2625965556","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625965556?lang=en_us&edition=fundamental","pubTime":"2026-04-08 03:56","pubTimestamp":1775591787,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 03:56 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nAQN2LTMJS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","YDES"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624850582","title":"YD Bio files Form 3 as director Kochi Chang reports no beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2624850582","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624850582?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:27","pubTimestamp":1775129256,"startTime":"0","endTime":"0","summary":"YD Bio reported Director Kochi Chang in an initial Form 3 filing dated March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. YD Bio Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL1hg9JX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YDES","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623324342","title":"YD Bio files Form 3; director Jerry Yin-Chia Lee reports no securities owned","url":"https://stock-news.laohu8.com/highlight/detail?id=2623324342","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623324342?lang=en_us&edition=fundamental","pubTime":"2026-03-31 05:30","pubTimestamp":1774906252,"startTime":"0","endTime":"0","summary":"YD Bio filed an initial Form 3 naming Jerry Yin-Chia Lee as a director, dated March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. YD Bio Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL30KLrd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","YDES"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622870739","title":"YD Bio files initial beneficial ownership statement; Chief Medical Officer and director Zhang Bo-Xiang reports 31,141 ordinary shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2622870739","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622870739?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:05","pubTimestamp":1774641937,"startTime":"0","endTime":"0","summary":"YD Bio files initial beneficial ownership statement; Chief Medical Officer and director Zhang Bo-Xiang reports 31,141 ordinary shares. YD Bio reported that director and Chief Medical Officer Bo-Xiang Zhang beneficially owns 31,141 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. YD Bio Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL3Rfgsq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YDES","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622689657","title":"YD Bio files initial beneficial ownership statement; CFO Edmund Hen reports no securities beneficially owned","url":"https://stock-news.laohu8.com/highlight/detail?id=2622689657","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622689657?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:02","pubTimestamp":1774555346,"startTime":"0","endTime":"0","summary":"YD Bio reported that Chief Financial Officer Edmund Hen filed an initial Form 3 statement dated 03/18/2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. YD Bio Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL4s6LL8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","YDES"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621981701","title":"YD Bio Ltd trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2621981701","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621981701?lang=en_us&edition=fundamental","pubTime":"2026-03-23 21:47","pubTimestamp":1774273638,"startTime":"0","endTime":"0","summary":"09:43 EDT YD Bio (YDES)Ltd trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/yd-bio-ltd-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/yd-bio-ltd-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["YDES","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621709741","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:43 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2621709741","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621709741?lang=en_us&edition=fundamental","pubTime":"2026-03-23 21:43","pubTimestamp":1774273401,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:43 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nAQN2LREZD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YDES","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620573762","title":"YD Bio Limited files Form 3 as CEO Ethan Shen reports 54.34 million ordinary shares owned","url":"https://stock-news.laohu8.com/highlight/detail?id=2620573762","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620573762?lang=en_us&edition=fundamental","pubTime":"2026-03-18 22:51","pubTimestamp":1773845498,"startTime":"0","endTime":"0","summary":"YD Bio reported an initial statement of beneficial ownership for Ethan Shen, its CEO and a director. Shen reported direct beneficial ownership of 11,224,153 ordinary shares. He also reported indirect beneficial ownership of 43,120,858 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. YD Bio Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL9KjJTV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","YDES"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620422689","title":"YD Bio details roadmap for integrated oncology ecosystem","url":"https://stock-news.laohu8.com/highlight/detail?id=2620422689","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620422689?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:36","pubTimestamp":1773751015,"startTime":"0","endTime":"0","summary":"YD Bio (YDES)highlighted the strategic roadmap shared by CEO Ethan Shen. YD Bio is building a comprehensive ecosystem that synchronizes diagnostic ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/yd-bio-details-roadmap-for-integrated-oncology-ecosystem-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/yd-bio-details-roadmap-for-integrated-oncology-ecosystem-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","YDES"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620421097","title":"YD Bio outlines plan to integrate cancer detection with dendritic cell immunotherapy by 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2620421097","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620421097?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:02","pubTimestamp":1773748969,"startTime":"0","endTime":"0","summary":"YD Bio outlined a strategy to build an integrated oncology ecosystem that links DNA methylation-based cancer detection with late-stage dendritic cell immunotherapy programs. The company plans to use diagnostic data to monitor and evaluate therapeutic response, creating a feedback loop intended to guide clinical decision-making. It also plans to expand regulatory-grade infrastructure by participating in global regulatory processes, including acting as an Official U.S. Agent for FDA submissions. YD Bio is targeting a conditional clinical pathway milestone in Taiwan by 2027 for its glioblastoma dendritic cell therapy. The company said it will follow a stepwise capital allocation approach focused on operational infrastructure, including collaborations with contract research organizations and manufacturing capabilities.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL1bQx52:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4112","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4585","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU0314104364.USD","YDES","SG9999014039.USD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4588","NDAQ","LU2210150020.SGD","LU2210149790.SGD","BK4139","IE00BKPKM429.USD","LU2095319765.USD","SG9999014005.SGD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614608700","title":"BRIEF-Yd Bio Limited Announces Strategic Partnership With Yc Biotech Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2614608700","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614608700?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:33","pubTimestamp":1772026434,"startTime":"0","endTime":"0","summary":"BRIEF-Yd Bio Limited Announces Strategic Partnership With Yc Biotech CoFeb 25 (Reuters) - YD Bio Ltd YDES.O:YD BIO LIMITED ANNOUNCES STRATEGIC PARTNERSHIP WITH YC BIOTECH CO., LTD. TO ESTABLISH A TAIW","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA9SXQSJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","YDES"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614566087","title":"BUZZ-YD Bio rises as it signs U.S. regulatory partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2614566087","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614566087?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:18","pubTimestamp":1772025500,"startTime":"0","endTime":"0","summary":"BUZZ-YD Bio rises as it signs U.S. regulatory partnership** Shares of Biotechnology company YD Bio YDES.O rise 3.97% to $8.38 premarket** Co says it signed a U.S. regulatory partnership with YC Biotech, an Asiabased technical and regulatory support firm, to help drug and device makers navigate FDA approvals** Co says it will act as YC Biotech's exclusive U.S. representative, handling FDA communication and guiding clients from early meetings to final submissions** YDES says the deal marks a shift toward a broader platform model that may expand into Europe** Co says partnership expected to boost service offerings and support client growth** Shares up ~8% in 2025  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL4N3ZL18J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","YDES"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}]}}